 1.0 mmol/
L (40 mg/dL) for this speciﬁc population was not
included, but it is acknowledged that in several countries
PCSK9 inhibitors are used to reach these goals in those
with recurrent cardiovascular events.
In line with the other cardiovascular risk reduction interventions in these usually frail, multimorbid individuals,
treatment and its goals should be based on shared decision making and should be individualised after careful
weighting of the beneﬁts